On Tuesday, Cytokinetics Inc (NASDAQ: CYTK) was 0.26% up from the session before settling in for the closing price of $54.70. A 52-week range for CYTK has been $25.98 – $110.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 12.30% over the last five years. When this article was written, the company’s average yearly earnings per share was at 17.26%. With a float of $110.87 million, this company’s outstanding shares have now reached $114.66 million.
The firm has a total of 423 workers. Let’s measure their productivity.
Cytokinetics Inc (CYTK) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cytokinetics Inc stocks. The insider ownership of Cytokinetics Inc is 3.30%, while institutional ownership is 100.94%. The most recent insider transaction that took place on Jul 01 ’24, was worth 621,575. In this transaction President & CEO of this company sold 11,500 shares at a rate of $54.05, taking the stock ownership to the 405,145 shares. Before that another transaction happened on Jul 01 ’24, when Company’s Director sold 5,000 for $54.22, making the entire transaction worth $271,100. This insider now owns 20,600 shares in total.
Cytokinetics Inc (CYTK) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 3/31/2024, it has been observed that the corporation posted -1.34 earnings per share (EPS) during the time that was less than consensus figure (set at -1.15) by -0.19. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.26% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to -22.79% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
You can see what Cytokinetics Inc (CYTK) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1676.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.40, a number that is poised to hit -1.05 in the next quarter and is forecasted to reach -4.37 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Analysing the last 5-days average volume posted by the [Cytokinetics Inc, CYTK], we can find that recorded value of 2.77 million was better than the volume posted last year of 2.72 million. As of the previous 9 days, the stock’s Stochastic %D was 80.62%. Additionally, its Average True Range was 2.36.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 24.47%, which indicates a significant decrease from 79.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.62% in the past 14 days, which was lower than the 54.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $56.95, while its 200-day Moving Average is $56.28. Now, the first resistance to watch is $55.41. This is followed by the second major resistance level at $55.98. The third major resistance level sits at $56.99. If the price goes on to break the first support level at $53.83, it is likely to go to the next support level at $52.82. Should the price break the second support level, the third support level stands at $52.25.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
There are 104,854K outstanding shares of the company, which has a market capitalization of 6.29 billion. As of now, sales total 7,530 K while income totals -526,240 K. Its latest quarter income was 840 K while its last quarter net income were -135,640 K.
